![Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics](https://pubs.rsna.org/cms/10.1148/rg.2021210005/asset/images/medium/rg.2021210005.tbl1.png)
Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics
![Frontiers | Stratification of ovarian cancer borderline from high-grade serous carcinoma patients by quantitative serum NMR spectroscopy of metabolites, lipoproteins, and inflammatory markers Frontiers | Stratification of ovarian cancer borderline from high-grade serous carcinoma patients by quantitative serum NMR spectroscopy of metabolites, lipoproteins, and inflammatory markers](https://www.frontiersin.org/files/Articles/1158330/fmolb-10-1158330-HTML-r2/image_m/fmolb-10-1158330-g001.jpg)
Frontiers | Stratification of ovarian cancer borderline from high-grade serous carcinoma patients by quantitative serum NMR spectroscopy of metabolites, lipoproteins, and inflammatory markers
![ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors - Timmerman - 2021 - Ultrasound in Obstetrics & Gynecology - Wiley Online Library ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors - Timmerman - 2021 - Ultrasound in Obstetrics & Gynecology - Wiley Online Library](https://obgyn.onlinelibrary.wiley.com/cms/asset/d5808b7e-6500-4bc7-b365-36846ba59089/uog23635-fig-0003-m.jpg)
ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors - Timmerman - 2021 - Ultrasound in Obstetrics & Gynecology - Wiley Online Library
![CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2001025641/2003896921/gr1.gif)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
![Evolving Role of Serum Biomarkers in the Management of Ovarian Cancer - Angiolo Gadducci, Stefania Cosio, Giulia Zanca, Andrea Riccardo Genazzani, 2006 Evolving Role of Serum Biomarkers in the Management of Ovarian Cancer - Angiolo Gadducci, Stefania Cosio, Giulia Zanca, Andrea Riccardo Genazzani, 2006](https://journals.sagepub.com/cms/10.2217/17455057.2.1.141/asset/images/large/10.2217_17455057.2.1.141-table5.jpeg)
Evolving Role of Serum Biomarkers in the Management of Ovarian Cancer - Angiolo Gadducci, Stefania Cosio, Giulia Zanca, Andrea Riccardo Genazzani, 2006
![PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a96fc01f495907ea18214fdc7db7ffd9b210d72c/2-TableI-1.png)
PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar
![Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics](https://pubs.rsna.org/cms/10.1148/rg.2021210005/asset/images/medium/rg.2021210005.va.gif)